BioMarin Pharmaceutical (BMRN) is back in focus after a mixed Q3 2026 update, with adjusted profit topping analyst expectations while sales came in slightly below forecasts and full year guidance moved lower. Recent trading tells a mixed story for BioMarin Pharmaceutical. The share price slipped 1.83% on the day to US$57.44 yet still shows a 3.03% gain over the past week, while a 90 day share price return down 5.40% contrasts with a 1 year total shareholder return of 8.69%. This suggests...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.
BioMarin Pharmaceutical (BMRN) just put fresh clinical data in front of investors, highlighting five year outcomes for POMBILITI plus OPFOLDA in late onset Pompe disease and early stage results for its nivudirsen program. BioMarin Pharmaceutical’s clinical updates arrive after a challenging spell for the stock, with the 30 day share price return down 17.03% and the 7 day move also weaker, while the 1 year total shareholder return remains close to flat at 0.93%. Scan BioMarin Pharmaceutical’s...
Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.
BioMarin shared five-year data showing a combination therapy helped adults with late-onset Pompe disease maintain motor function.
Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates.
BioMarin Pharmaceutical Inc. stock outlook: Q4 2026–2027 catalysts, DMD BMN 351 data, Voxzogo approval potential, and raised guidance. Click for this BMRN update.
This is the newest page. Registered accounts read further back.